Jasper Therapeutics, Inc.
JSPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $83,373 | $64,595 | $311,827 |
| - Cash | $50,899 | $39,510 | $48,799 | $71,637 |
| + Debt | $0 | $2,155 | $2,590 | $1,813 |
| Enterprise Value | – | $46,018 | $18,386 | $242,003 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$18,507 | -$26,818 | -$21,523 | -$25,040 |
| % Margin | – | – | – | – |
| Net Income | -$18,736 | -$26,723 | -$21,241 | -$24,321 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.13 | -1.74 | -1.41 | -1.62 |
| % Growth | 35.1% | -23.4% | 13% | – |
| Operating Cash Flow | -$16,999 | -$15,453 | -$22,842 | -$21,134 |
| Capital Expenditures | $0 | -$7 | $0 | -$96 |
| Free Cash Flow | -$16,999 | -$15,460 | -$22,842 | -$21,230 |